Table 8 Literature verification of predicted direct compound-cardiovascular disease interactions
Predicted interactions | Validated literatures |
|---|---|
Borneol (C8)—Hyperlipidemia (D16) | Borneol has ameliorative effect of hyperlipidemia in diabetic Wistar rats [32] |
Cryptotanshinone (C10)—Diabetes mellitus type 2 (D20) | Cryptotanshinone has effect of antidiabetes via activation of AMP-activated protein kinase [33] |
Ginsenoside-Rg1 (C18)—Diabetes mellitus type 2 (D20) | Ginsenoside-Rg1 can alleviate the insulin resistance through increasing the uptake of glucose and decreasing the output of glucose [34, 35] |
Tanshinone IIA (C40)—Diabetes mellitus type 2 (D20) | Tanshinone IIA may alleviate type 2 DM symptoms in experimental rats [36] |
Cryptotanshinone (C10)—Obesity (D12) | Cryptotanshinone promotes commitment to the brown adipocyte lineage and mitochondrial biogenesis in C3H10T1/2 mesenchymal stem cells to alleviate obesity [37] |
Tanshinone IIA (C40)—Obesity (D12) | Tanshinone IIA may treat obesity through PPARγ [38] |
Tanshinone IIA (C40)—Angina pectoris (D18) | Sodium tanshinone IIA silate can act as an add-on therapy in patients with unstable angina pectoris [39] |
Ginsenoside-Rg1 (C18)—Acute Myocardial infarction (D1) | Ginsenoside-Rg1 could enhance angiogenesis and ameliorates ventricular remodeling in a rat model of Acute Myocardial infarction [40] |